Version 1
: Received: 26 October 2023 / Approved: 27 October 2023 / Online: 30 October 2023 (06:54:10 CET)
How to cite:
Redondo, S.; Perez de Oteyza, J. The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer. Preprints2023, 2023101750. https://doi.org/10.20944/preprints202310.1750.v1
Redondo, S.; Perez de Oteyza, J. The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer. Preprints 2023, 2023101750. https://doi.org/10.20944/preprints202310.1750.v1
Redondo, S.; Perez de Oteyza, J. The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer. Preprints2023, 2023101750. https://doi.org/10.20944/preprints202310.1750.v1
APA Style
Redondo, S., & Perez de Oteyza, J. (2023). The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer. Preprints. https://doi.org/10.20944/preprints202310.1750.v1
Chicago/Turabian Style
Redondo, S. and Jaime Perez de Oteyza. 2023 "The Journey to Clonal Hematopoiesis and Applications Incardiovascular Disease and Cancer" Preprints. https://doi.org/10.20944/preprints202310.1750.v1
Abstract
: For a long time, atherosclerosis has been regarded as a mere lipid deposit in the blood vessels. However, in the recent years a growing body of experimental and clinical evidence have highlighted the role of inflammation and immunity as a central mechanism of disease. Moreover, in the last decade the coming of next-generation sequencing and its application to large human population has broken the barrier between inflammation and cancer. Indeed, acquired mutation in key genes related to the control of hematopoiesis and myeloproliferation have paved the way to establish the new concept of clonal hematopoiesis of indeterminate potential. This phenomenon is being considered not such “indeterminate”, but as an emerging cardiovascular risk factor. Thus, this may explain the mechanisms of myeloproliferation and inflammation in atherosclerosis. And in a bidirectional journey, it has helped to explain the extremely high cardiovascular risk in cancer survivors, in particular in myeloprolfierative neoplasm patients. A deeper understanding of these mechanisms may pave the way for the future early diagnosis and potential preemptive treatments of the leading worldwide cause of death.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
